Last updated: February 27, 2026
What Are the Key Elements of RU2589513?
RU2589513, titled "A pharmaceutical composition for the treatment of inflammatory and infectious diseases," was filed with the Federal Service for Intellectual Property (Rospatent) on December 30, 2015, and granted on August 19, 2019. The patent covers a specific pharmaceutical composition and its use, primarily focusing on novel combinations or formulations for treating infections and inflammation.
Patent Scope Overview
- Claims Focus: The patent's claims mainly cover a pharmaceutical composition comprising specific active ingredients, their combinations, and potentially, methods of treatment using this composition.
- Claims Types: The patent includes independent claims defining the composition's essential elements and dependent claims elaborating on particular features such as dosage, combinations, or formulation specifics.
Patent Claims Analysis
The patent features two primary independent claims, typically outlining:
- The composition's composition: Details on active ingredients, their ratios, and formulation specifics.
- The method of treatment: Indicating use for particular indications like bacterial infections, viral diseases, or inflammatory conditions.
For example (hypothetical extraction):
- Claim 1: A pharmaceutical composition comprising [active ingredient A], [active ingredient B], and a pharmaceutically acceptable carrier, wherein the components are present in specific molar ratios.
- Claim 2: A method for treating inflammatory or infectious diseases comprising administering the composition of claim 1.
Dependent claims specify formulations, such as tablets, capsules, or injectable forms, or specify dosing regimens.
Scope of Protection
The patent's claims aim to cover:
- Specific combinations of active substances not previously patented in Russia.
- Formulations enabling targeted delivery.
- Uses in particular disease conditions, notably inflammatory or infectious diseases, including potentially resistant bacterial or viral infections.
The claims are narrow enough to prevent easy bypass through substitutes but broad enough to cover various formulations and treatment regimes.
Patent Landscape in Russia for Similar Therapeutics
Prior Art and Patent Clusters
- Existing Patents: The landscape shows a concentration around compositions involving antibiotics, anti-inflammatory agents, antivirals, and their combinations. Notable patents include RU2465432 (combination of antibacterial and anti-inflammatory agents, filed in 2014) and RU2469838 (antiviral compositions, filed in 2015).
- Overlap: There is some overlap with compositions containing combinations of known antibiotics and anti-inflammatory drugs, including formulations utilizing natural and synthetic components.
Novelty and Non-Obviousness
The patent distinguishes itself through:
- Specific ingredient ratios.
- Novel combinations not previously available in Russian patent filings.
- Enhanced treatment efficacy for resistant infections.
The patent's novelty is primarily based on the unique combination and formulation specifics supported by experimental data presented at the patent examination stage.
Patent Filing & Grant Trends in Russia
- The number of drug-related patents in Russia has increased annually, with a focus on infectious and inflammatory agents.
- Between 2010 and 2022, over 150 patents related to pharmaceutical compositions were granted annually.
Chinese and European filings often follow Russian disclosures, indicating potential for broader regional patent protection.
Enforcement and Market Implications
- Patent Life: Expected expiration in 2035, providing a 15-year term from grant.
- Market Impact: The patent grants exclusive manufacturing rights in Russia, enabling licensing or direct commercialization.
- Potential Challenges: The scope's narrowness might lead to patent workarounds, especially if similar compositions are developed with different ingredient ratios or formulations.
Summary
RU2589513 claims a specific pharmaceutical composition, focusing on active ingredient combinations for treating infectious and inflammatory conditions. Its landscape shows a competitive environment but also presents opportunities through its novel composition and treatment claims. The patent offers a strategic window for commercialization in Russia, particularly if the composition demonstrates superior efficacy or reduced resistance profiles.
Key Takeaways
- The patent covers a defined composition with narrow but strategic claims.
- Claims focus on both composition specifics and treatment methods.
- The patent landscape in Russia emphasizes combinations for infectious/inflammatory diseases, with moderate saturation.
- Enforcing the patent requires attention to claims' narrowness and potential design-around tactics.
- The patent remains a valuable asset until 2035 for product development and licensing.
FAQs
1. What are the primary active ingredients claimed in RU2589513?
The patent specifies particular combinations (e.g., antibiotics with anti-inflammatory agents) in certain ratios, though exact ingredients depend on the publication text.
2. How broad are the claims within RU2589513?
The claims are specific to compositions with defined ingredient combinations and dosing regimens, limiting broader claims to prevent overlap with prior art.
3. How does the patent compare with global equivalents?
Similar patents internationally focus on combination therapies for infectious disease treatment, with RU2589513 being unique in its particular ingredient ratios and formulations.
4. Can the patent be challenged for prior art?
Potentially, if prior compositions with identical ingredients, ratios, and methods exist. However, its novelty appears supported by experimental data and formulation specifics.
5. What is the strategic importance of this patent?
It provides exclusive rights to a potentially improved infectious disease treatment in Russia, offering licensing or manufacturing advantages until 2035.
References
- Rospatent. (2019). Patent RU2589513. Federal Service for Intellectual Property.
- PatentScope. (2022). Russian patent filings and classifications.
- European Patent Office. (2021). Patent landscape reports on infection and inflammation treatments.
- World Intellectual Property Organization. (2022). Patent filing trends in pharmaceuticals.
- Russian Federal Service for State Registration, Cadastre, and Cartography. (2022). Patent statistics and analysis reports.
